PDGFRB and gastrointestinal stromal tumor: Pazopanib, an inhibitor for VEGFR, PDGFR, FGFR, c-kit, and many other tyrosine kinases [28,29], has suppressive effects on angiogenesis and has been approved for the treatment of non-GIST soft tissue sarcomas [30,31,32].